Additional details on the interim analyses in the PC-study Authors: Annabelle van Gils, Eva Pajkrt Published: 2026 This letter was written following an editorial request to provide more information on the interim analyses of the PC-study.1 Recruitment for the PC-study was halted following the results of the third interim analysis due to safety concerns and the apparent challenge in establishing non-inferiority of pessary treatment. Here, we present additional information regarding this interim analysis. In November 2018 the first planned interim analysis was performed (including 110 participants), after which the Data safety Monitoring Board (DSMB) advised to continue the study and to perform an additional (second) interim analysis at 150 participants. To do so, an amendment was submitted to the Medical Ethics Review Committee. No reason for additional analysis was provided, as the DSMB invoked its rights and obligations as stated in the DSMB charter, stating that “the DSMB does not have the right to share confidential information with anyone outside the DSMB and that they may commission additional safety reviews”. This second interim analysis was performed on the primary endpoint of 150 participants, after which they advised to continue the trial according to protocol and to perform the next (third) interim analysis following 200 participants reaching the primary endpoint. Ultimately this third interim analysis led to the decision to halt recruitment of the trial, based on safety concerns (perinatal morbidity and mortality) and the apparent challenge to establish non-inferiority of pessary treatment. The third interim analysis included 112 participants randomized to pessary treatment and 114 to cerclage treatment. The primary outcome of preterm birth <32 weeks occurred in 35% of participants in the pessary group vs. 25% in the cerclage group. In the final analysis, these results were 33.8% vs 24.0%, respectively. Stillbirth and neonatal death were reported 26% in the pessary group vs. 15% in the cerclage group. In the final analysis, these were 22.3% vs 14.4% respectively. Based on these results, the DSMB recommended not to continue the trial from a safety perspective, while sufficient data appeared to be available to exclude the possibility of non-inferiority of pessary treatment as compared to cerclage after completion of the trial. Contributors EP was the principal investigator at Amsterdam University Medical Centre and is guarantor for the report. AvG drafted this letter with supervision of EP. Declaration of interests The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EP is board member of Stichting Stoptevroegbevallen, a non-profit organization supporting preterm birth research and received payments to the institution. AvG declares no competing interests. Reference